D. Boral Capital Reaffirms “Buy” Rating for Checkpoint Therapeutics (NASDAQ:CKPT)

Checkpoint Therapeutics (NASDAQ:CKPT)‘s stock had its “buy” rating reiterated by stock analysts at D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $4.80 price objective on the stock. D. Boral Capital’s target price indicates a potential upside of 18.81% from the company’s current price.

Other equities analysts have also recently issued research reports about the company. HC Wainwright reiterated a “neutral” rating and issued a $4.10 price objective on shares of Checkpoint Therapeutics in a research note on Tuesday, March 11th. Lake Street Capital reiterated a “hold” rating and issued a $4.10 price target (down previously from $7.00) on shares of Checkpoint Therapeutics in a research note on Monday, March 10th.

Checkpoint Therapeutics Price Performance

Shares of NASDAQ:CKPT opened at $4.04 on Monday. The firm has a market capitalization of $197.29 million, a PE ratio of -2.20 and a beta of 1.41. Checkpoint Therapeutics has a 1 year low of $1.38 and a 1 year high of $4.50. The firm’s 50-day moving average is $3.32 and its two-hundred day moving average is $3.27.

Checkpoint Therapeutics (NASDAQ:CKPT) last announced its earnings results on Friday, March 28th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.47). Analysts expect that Checkpoint Therapeutics will post -0.94 EPS for the current fiscal year.

Insider Activity

In other news, CEO James F. Oliviero III sold 10,331 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $3.15, for a total transaction of $32,542.65. Following the completion of the sale, the chief executive officer now owns 3,775,019 shares in the company, valued at approximately $11,891,309.85. The trade was a 0.27 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO William Garrett Gray sold 74,110 shares of the stock in a transaction on Thursday, February 6th. The shares were sold at an average price of $3.67, for a total transaction of $271,983.70. Following the completion of the transaction, the chief financial officer now directly owns 1,458,644 shares in the company, valued at $5,353,223.48. This trade represents a 4.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 93,674 shares of company stock worth $336,011. 2.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Checkpoint Therapeutics

Large investors have recently bought and sold shares of the stock. Wealth Enhancement Advisory Services LLC increased its position in shares of Checkpoint Therapeutics by 226.9% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 425,000 shares of the company’s stock worth $1,360,000 after purchasing an additional 295,000 shares in the last quarter. 683 Capital Management LLC purchased a new position in Checkpoint Therapeutics during the 4th quarter worth approximately $522,000. Geode Capital Management LLC increased its position in Checkpoint Therapeutics by 41.2% during the third quarter. Geode Capital Management LLC now owns 427,651 shares of the company’s stock worth $958,000 after buying an additional 124,787 shares during the period. OMERS ADMINISTRATION Corp purchased a new stake in Checkpoint Therapeutics in the fourth quarter valued at approximately $374,000. Finally, Bank of America Corp DE boosted its holdings in shares of Checkpoint Therapeutics by 30,216.8% in the fourth quarter. Bank of America Corp DE now owns 90,041 shares of the company’s stock valued at $288,000 after acquiring an additional 89,744 shares during the period. Institutional investors and hedge funds own 22.00% of the company’s stock.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.